Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
M6P/IGF2R allele loss was also found in cirrhotic tissue of clonal origin adjacent to these dysplastic lesions and HCCs, demonstrating that M6P/IGF2R inactivation occurs early in liver carcinogenesis.
|
9294214 |
1997 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
RT‑PCR demonstrated that the mRNA expression levels of IGF2R were downregulated in HCC compared with in TST samples (P=0.004), which was associated with a worse recurrence‑free survival of patients with HCC (P=0.002) and a lower occurrence of cirrhosis (P=0.05).
|
30720132 |
2019 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
|
18322954 |
2008 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The combination of IGF-2+3580 AA homozygosity and IGF-2R 1619 GG homozygosity presented a significant protective effect against HCC (OR=0.16,95% CI=0.08-0.34, P=0.005).
|
24656929 |
2014 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, M6P/IGF2R is mutated in HCCs from throughout Japan with a frequency similar to that in the United States.
|
11981765 |
2002 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The latter is homologous to the human M6P/IGF2r coding sequence which is mutated in human hepatocellular carcinoma.
|
10411141 |
1999 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
DX-2647, a recombinant human antibody, potently neutralizes the action of insulin-like growth factor-II (IGF-II), a ligand for three cell-surface receptors (IGF-IR, insulin receptor A and B isoforms, and the cation-independent mannose-6-phosphate receptor) which is overexpressed in primary human HCC.
|
29933129 |
2018 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Moreover, these M6P/IGF2R 3'UTR mutations and the TP53 mutations detected previously were mutually exclusive in most of the tumors, suggesting two independent pathways to HCC development, with the TP53 pathway being more favored with increasing radiation dose than the M6P/IGF2R pathway.
|
17149973 |
2006 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.
|
7493029 |
1995 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.
|
7639583 |
1995 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Compared with corresponding non-tumor tissues, expression of the M6P/IGF2R mRNA was decreased in 13/19 (68%) HBV-positive HCC tissues, suggesting that M6P/IGF2R may be involved in HBV-associated hepatocarcinogenesis by the regulation of its expression level.
|
12736721 |
2003 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recently, it was reported in the United States that loss of heterozygosity (LOH) and mutations in exons 27, 28, and 31 of the M6P/IGF2R gene are frequent in hepatocellular carcinomas (HCCs) and adenomas.
|
10347113 |
1999 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The frequent allelic loss and homozygous deletion of the M6P/ IGF2r gene suggest that the M6P/IGF2r gene functions as a tumor suppressor gene in the development of HCC.
|
9570384 |
1997 |
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
This study is the first to find that the M6P/IGF2R gene is inactivated in prostate cancer.
|
16304558 |
2006 |
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
In contrast, Man-6-P/IGF2R binding of endogenous, full-length uPAR solubilized from plasma membranes of the prostate cancer cell line, PC-3, was not inhibited by Man-6-P. Further studies showed that very little (<5%) endogenous uPAR was Man-6-P/IGF2R binding-competent.
|
12665524 |
2003 |
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
We chose the strategy to develop a novel compound that allows the improvement of the targeting of the cation-independent mannose 6-phosphate receptor, which is overexpressed in prostate cancer.
|
31181759 |
2019 |
Alzheimer's Disease
|
0.320 |
Biomarker
|
disease |
BEFREE |
Together, these results highlight the potential contribution of IGF-II receptor to AD pathology not only by regulating expression/processing of APP but also by its role in cellular vulnerability.
|
25939386 |
2015 |
Parkinson Disease
|
0.320 |
Biomarker
|
disease |
BEFREE |
These data indicate MPR300 as crucial player in the autophagy-lysosomal dysfunctions reported in PD and pinpoint MRP300 as a potential biomarker for PD.
|
27509067 |
2016 |
Parkinson Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
While PD-linked point mutant Vps35 D620N interacts with the cation-independent mannose-6-phosphate receptor (CI-M6PR), a known retromer cargo, we find that its expression disrupts the trafficking of cathepsin D, a CI-M6PR ligand and protease responsible for degradation of α-synuclein, a causative agent of PD.
|
24152121 |
2014 |
Fetal Growth Retardation
|
0.240 |
Biomarker
|
phenotype |
BEFREE |
IGF2R expression was significantly decreased in placentas from pregnancies complicated by idiopathic FGR (P < 0.05 versus control). siRNA-mediated IGF2R knockdown in term placental explants and the trophoblast cell line BeWo resulted in altered expression of homeobox gene transcription factors, including increased expression of distal-less homeobox gene 5 (DLX5), and decreased expression of H2.0-Like Homeobox 1 (HLX) (P < 0.05 versus control).
|
31418778 |
2019 |
Fetal Growth Retardation
|
0.240 |
GeneticVariation
|
phenotype |
BEFREE |
The infant with IUGR has a higher serum level of IGF2 if has A/G IGF2-ApaI genotype and higher values of IGF2R if it has the A/A genotype.
|
28460554 |
2018 |
Fetal Growth Retardation
|
0.240 |
Biomarker
|
phenotype |
BEFREE |
There was no significant difference in the levels of transcripts for IGF1, insulin receptor, or IGF2R between normal and IUGR term placentas.
|
9491374 |
1998 |
Fetal Growth Retardation
|
0.240 |
AlteredExpression
|
phenotype |
BEFREE |
When compared to age-matched appropriate for gestational age (AGA) infants, expression of PHLDA2 (p = 0.03) IGF2R (p < 0.05) was upregulated in IUGR infants.
|
22154689 |
2012 |
Coronary Artery Disease
|
0.110 |
Biomarker
|
disease |
BEFREE |
In patients with NOCAD, myocardium with IMR <25 U had normal MPRI (1.9 ± 0.4 vs. controls 2.0 ± 0.3; p = 0.49); myocardium with IMR ≥25 U had significantly impaired MPRI, similar to ischemic myocardium downstream of obstructive CAD (1.2 ± 0.3 vs. 1.2 ± 0.4; p = 0.61).
|
29495996 |
2018 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The urine CD222 levels were increased specifically in breast cancer and multiple myeloma.
|
29940770 |
2018 |